РОЛЬ ДЕПО-ФОРМ ЛЕЙПРОРЕЛИНА АЦЕТАТА (ЛЮКРИН ДЕПО®)В ЛЕЧЕНИИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
https://doi.org/10.17650/1726-9776-2009-5-1-64-67
Аннотация
Роль депо-форм лейпрорелина ацетата (Люкрин депо®)в лечении рака предстательной железы
Список литературы
1. Аксель Е.М. Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в Рос-сии в 2003 г. Онкоурология 2005;(1):6—9.
2. Huggins C., Hodges C.V. Studies onprostatic cancer. I. The effect of castration,of estrogen and of androgen injection onserum phosphatases in metastatic carcino-ma ofthe prostate. Cancer Res 1941;1:293-7.
3. Barreca T., Martorana G., Franceschini R. et al. Suppression of testic-ular androgenesis by D-tryptophan-6-luteinizing hormone-releasing hormonedoes not affect TSH secretion in male sub-jects. Horm Res 1986;23(3):181-4.
4. Инструкция к препарату Люкрин-Депо, П №15554/01—170308.
5. Periti P., Mazzei T., Mini E. Clinicalpharmacokinetics of depot leuprorelin.Clin Pharmacokinet 2002;41(7):485—504.
6. Mazzei T., Mini E., Eandi M. et al.Pharmacokinetics, endocrine and antitu-mour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation. Drugs Exp Clin Res1989;15(8):373—87.
7. Kienle E., Lubben G. Efficacy and safe-ty of leuprorein depot for prostate cancer.Urol Int 1996;56(suppl 1):23—30.
8. Bischoff W., German Leuprorelin StudyGroup. 3,75 and 7,5 mg leuprorelin acetatedepot in the treatment of advanced prostatecancer: preliminary report. J Int Med Res1990;18(suppl 1):103—13.
9. Crawford E.D., Blumenstein B.A.,Goodman P.J. et al. Leuprolide with andwithout flutamide in advanced prostatecancer. Cancer 1990;66(5 Suppl):1039—44.
10. Sato K., Akakura S., Isaka H. et al.Intermittent androgen suppression forlocally advanced and metastatic prostatecancer: Preliminary report of a prospectivemulticenter study1. Urology2004;64(2):341—5.
11. Prezioso D., Lotti T., Polito M.,Montironi R., onbehalf of the NeoadjuvantStudy Group. Neoadjuvant hormone treat-ment with leuprolide acetate depot 3,75 mgand cyproterone acetate, before radicalprostatectomy: a randomized study. UrolInt 2004;72:189—95.
12. Leuprolide versus diethylstilbestrol formetastatic prostate cancer. The LeuprolideStudy Group. N Engl J Med1984;311:1281—6.
13. Heyns C.F., Simonin M.P., Grosgurin P. et al. For the South AfricanTriptorelin Study Group. Comparative effi-cacy of triptorelin pamoate and leuprolideacetate in men with advanced prostate can-cer. BJU Int 2003;92(3):226—31.
14. Аbbou C.C., Lucas C., Leblanc V.Tolerance and clinical and biologicalresponses during the first 6 months of treat-ment with 1-month sustained releaseLHRH agonists leuprolerin and triptolerinin patients with metastatic prostate cancer.Prog Urol 1997;7(6):984—95.
15. Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy andro-gen suppression in men with advancedprostate cancer: a systematic review andmeta-analysis. Ann Intern Med2000;132:566—77.
16. McLeod D., Zinner N., Gleason D. et al. for the Abarelix-Depot Study Group.Abarelix-depot (A-D) versus leuprolideacetate (L) for prostate cancer: results of amulti-institutional, randomized, phase IIIstudy in 271 patients. Proc Am Soc ClinOncol 2000;19:abstr 1306.
Рецензия
Для цитирования:
Волкова М.И. РОЛЬ ДЕПО-ФОРМ ЛЕЙПРОРЕЛИНА АЦЕТАТА (ЛЮКРИН ДЕПО®)В ЛЕЧЕНИИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ. Онкоурология. 2009;5(1):64-67. https://doi.org/10.17650/1726-9776-2009-5-1-64-67
For citation:
Volkova M.I. ROLE OF LEUPRORELINE ACETATE DEPOT (LUCRIN DEPOT®) FORMULATIONS IN THE TREATMENT OF PROSTATE CANCER. Cancer Urology. 2009;5(1):64-67. (In Russ.) https://doi.org/10.17650/1726-9776-2009-5-1-64-67
Просмотров:
669
Послать статью по эл. почте 
